Qsar and drug design ppt

65
Molecular Descriptors and Molecular Descriptors and Virtual Virtual Screening using Datamining Screening using Datamining approach approach Abhik Seal Abhik Seal OSDD Cheminformatics OSDD Cheminformatics

description

The ppt describes Molecular descriptors and MAchine learning terms how its useful in chem informatics

Transcript of Qsar and drug design ppt

Page 1: Qsar and drug design ppt

Molecular Descriptors and Molecular Descriptors and Virtual Virtual

Screening using Datamining Screening using Datamining approachapproach

Abhik Seal Abhik Seal OSDD CheminformaticsOSDD Cheminformatics

Page 2: Qsar and drug design ppt

Aim of Cheminformatics Aim of Cheminformatics Project Project To screen molecules interacting with

the Potential TB targets using classifiers.

Select the selected molecules and dock with Targets to further screen the molecules for leads.

Use cheminformatics techniques such as QSAR ,3D qsar, ADMET to look for potential leads and design Drugs using the leads – by building combinatorial libraries.

Page 3: Qsar and drug design ppt

Tuberculosis Tuberculosis Obstacles For Drug Design HIV-epidemic that has dramatically increased risk for

developing active TB. increasing emergence of multi-drug resistant TB (MDR-TB) emergence of extensively drug-resistant (XDR) TB strains XDR-TB is characterized by resistance to at least the two

first-line drugs rifampicin and isoniazid and additionally to a fluoroquinolone and an injectable drug- kanamycin

Existing TB drugs are therefore only able to target actively growing bacteria through the inhibition of cell processes such as cell wall biogenesis and DNA replication.

TB chemotherapy characterized by an efficient bactericidal activity but an extremely weak sterilizing activity i.e inability to kill slowly growing and slowly metabolizing strains.

Page 4: Qsar and drug design ppt

Drugs Currently in Drugs Currently in DevelopmentDevelopment

Expected timelines towards approval of candidate drugs currently in clinical stage of development(Sources: Global TB Alliance Annual report 2004-2005;StopTBPartnership Working Group on New Drugs forTB. Strategic Plan 2006-2015)

Page 5: Qsar and drug design ppt

Commonly Used TB drugs and Commonly Used TB drugs and TargetsTargets

Page 6: Qsar and drug design ppt

Main Properties of Anti TB drugsMain Properties of Anti TB drugs

Page 7: Qsar and drug design ppt

QSAR and Drug DesignQSAR and Drug Design

Compounds + biological activity

New compounds with improved biological activity

QSAR

Page 8: Qsar and drug design ppt

What is QSAR?What is QSAR?

QSAR is a mathematical relationship between a biological activity of a molecular system and its geometric and chemical characteristics.

A general formula for a quantitative structure-activity relationship

(QSAR) can be given by the following:

activity = f (molecular or fragmental properties)

QSAR attempts to find consistent relationship between biological activity and molecular properties, so that these “rules” can be used to evaluate the activity of new compounds.

Page 9: Qsar and drug design ppt

Molecule PropertiesMolecule Properties

SPC : Structure Property SPC : Structure Property CorrelationCorrelation

INTRINSIC PROPERTIESINTRINSIC PROPERTIES Molar Volume Connectivity Indices Charge Distribution Molecular WeightPolar surface Area...........

INTRINSIC PROPERTIESINTRINSIC PROPERTIES Molar Volume Connectivity Indices Charge Distribution Molecular WeightPolar surface Area...........

MOLECULE STRUCTUREMOLECULE STRUCTURE

CHEMICAL PROPERTIESCHEMICAL PROPERTIESpKaLog PSolubilityStability

CHEMICAL PROPERTIESCHEMICAL PROPERTIESpKaLog PSolubilityStability

BIOLOGICAL PROPERTIESBIOLOGICAL PROPERTIESActivityToxicityBiotransformationPharmacokinetics

BIOLOGICAL PROPERTIESBIOLOGICAL PROPERTIESActivityToxicityBiotransformationPharmacokinetics

Page 10: Qsar and drug design ppt

o Molecular descriptors are numerical values that characterize properties of molecules.

o The descriptors fall into Four classes . a) Topological b) Geometrical c) Electronic d) Hybrid or 3D Descriptors

Molecule DescriptorsMolecule Descriptors

Page 11: Qsar and drug design ppt

Classification of DescriptorsClassification of Descriptors

Topological Descriptors Topological Descriptors

Topological descriptors are derived directly from the connection table representation of the structure which include:

a) Atom and Bond Counts

b) substructure counts

c) molecular connectivity Indices (Weiner Index , Randic Index, Chi Index)

d) Kappa Indices

e) path descriptors

f) distance-sum Connectivity

g) Molecular Symmetry

Page 12: Qsar and drug design ppt

Geometrical DescriptorsGeometrical Descriptors

Geometrical descriptors are derived from the three-dimensional representations and include:

a) principal moments of inertia,

b) molecular volume,

c)solvent-accessible surface area,

d) Charged partial Surface area

e) Molecular Surface area

Page 13: Qsar and drug design ppt

Electronic DescriptorsElectronic Descriptors

Electronic descriptors characterize the molecular Strcutures with such

quantities :

a)dipole moment, b)Quadrupole moment, c) polarizibility, d)HOMO and LUMO energies, e)Dielectric energyf) Molar Refractivity

Page 14: Qsar and drug design ppt

Hybrid and 3D DescriptorsHybrid and 3D Descriptorsa) geometric atom pairs and

topological torsionsb) spatial autocorrelation vectorsc) WHIM indicesd) BCUTse) GETAWAY descriptorsf) Topomersg) pharmacophore fingerprintsh) Eva Descriptorsi) Descriptors of Molecular Field

Page 15: Qsar and drug design ppt

Limit Of DescriptorsLimit Of DescriptorsThe data set should contain at least 5 times as many compounds as descriptor in the QSAR.

The reason for this is that too few compounds relative to the number of descriptors will give

a falsely high correlation:

2 point exactly determine a line. 3 points exactly determine a plane (etc.) A data set of drug candidate that is similar

in size meaningless correlation

Page 16: Qsar and drug design ppt

Tools To calculate Molecular Tools To calculate Molecular Descriptors Freely availableDescriptors Freely availableCDK tool http://rguha.net/code/java/cdkdesc.html POWER MV

http://nisla05.niss.org/PowerMV/?q=PowerMV/

MOLD2 http://www.fda.gov/ScienceResearch/BioinformaticsTools/Mold2/default.htm

PADEL Descriptor

http://www.downv.com/Windows/install-PaDEL- Descriptor-10439915.htm

Page 17: Qsar and drug design ppt

Admet Descriptors to Screen Molecules

Page 18: Qsar and drug design ppt

BioavailabilityBioavailability The Bioavailability of a compound is

classified as :Bioavailability

Absorbtion Liver Metabolism

Permeability Gut-wall Metabolism

Transporters

Lipophilicity Solubility Flexibility

Hydrogen Bonding

Molecular Size/Shape

Page 19: Qsar and drug design ppt

PREDICTION OF PREDICTION OF ADMET PROPERTIESADMET PROPERTIESRequirements for a drug:

◦ Must bind tightly to the biological target in vivo

◦ Must pass through one or more physiological barriers (cell membrane or blood-brain barrier)

◦ Must remain long enough to take effect◦ Must be removed from the body by

metabolism, excretion, or other meansADMET: Absorption, Distribution,

metabolism, Excretion (Elimination), Toxicity

Page 20: Qsar and drug design ppt

Lipinski Rule of Five(Oral Drug Lipinski Rule of Five(Oral Drug Properties)Properties)Poor absorption or permeation is

more likely when:◦MW > 500◦LogP >5◦More than 5 H-bond donors (sum of

OH and NH groups)◦More than 10 H-bond acceptors (sum

of N and O atoms)

Page 21: Qsar and drug design ppt

Polar Surface AreaPolar Surface Areao Defined as amount of molecular surface(vander-walls) arising

from polar atoms(Nitrogen and oxygen atom together with attached hydrogens)

o PSA seems to optimally encode those drug properties which play an important role in membrane penetration: molecular polarity, H - bonding features and also solubility.

o It provide excellent correlations with transport properties of drugs.(PSA used in the Prediction of Oral absorbtion,Brain penetration, Intestinal Absorption, Caco-2- permeability)

o It has also been effectively used to characterize drug likeness during virtual screening & combinatorial library design.

o The calculation of PSA, however, is rather time-consuming because of the necessity to generate a reasonable 3Dmolecular geometry and the calculation of the surface itself.

o Peter Ertl introduced an extremely rapid method to obtain PSA descriptor simply from the sum of contributions of polar fragments in a molecule without the necessity to generate its three - dimensional (3D) geometry.

Page 22: Qsar and drug design ppt

PSA In Intestinal absorptionPSA In Intestinal absorption Intestinal absorption is usually expressed as fraction absorbed

(FA), expressing the percentage of initial dose appearing in a portal vein.

A model for PSA was done for the β - adrenoreceptor antagonists[1].A excellent sigmoidal relationship between PSA and FA after oral administration was obtained. Similar sigmoidal relationships can also be obtained for the topological PSA (TPSA).

These results suggest that drugs with a PSA < 60 Å 2 are completely (more than 90%) absorbed, whereas drugs with a PSA > 40 Å are absorbed to less than 10%.This conclusion was later confirmed with the correct classification of a set endothelin receptor antagonists as having either low, intermediate or high permeability.

PSA was also shown to play an important role in explaining human in vivo jejunum permeability[2]. A Model based on PSA and LogP for the prediction of drug absorption was developed for 199 well absorbed and 35 poorly absorbed compounds[3].

Page 23: Qsar and drug design ppt

PSA In Blood brain barrier PSA In Blood brain barrier penetration(BBB)penetration(BBB)

Drugs that act on the CNS need to be able to cross the BBB in order to reach their target, while minimal BBB penetration is required for other drugs to prevent CNS side effects.

A common measure of BBB penetration is the ratio of drug conc’s in the brain and the blood, which is expressed as log (C brain /Cblood ).

Van de Waterbeemd and Kansy were probably the first to correlate the PSA of a series of CNS drugs to their membrane transport. They obtained a fair correlation of brain uptake with single conformer PSA and molecular volume descriptors.

Clark etal. Derived a model of 55 compounds using TPSA and LogP

LogBB= 0.516-0.115* TPSA

n= 55 r2 =0.686 r= 0.828 σ = 0.42

TPSA in combiantion with ClogP

LogBB= 0.070-0.014*TPSA+0.169*ClogP

n=55 r2 =0.787 r=0.887 σ =0.35 Great majority of orally administered CNS drugs have a PSA <70 Å2 . Non CNS

compounds suggested that these have a PSA < 120Å2 . Thus to conclude a majority of the Non CNS penetrating and orally absorbed

compounds have PSA values between 70 and 120 A2.

.

Page 24: Qsar and drug design ppt

1-Octanol is the most frequently used lipid phase in pharmaceutical research. This is because:

It has a polar and non polar region (like a membrane phospholipid) Po/w is fairly easy to measure Po/w often correlates well with many biological properties It can be predicted fairly accurately using computational models

Xaqueous Xoctanol

P

Partition coefficient P (usually expressed as log10P or logP) is defined as:

P =[X]octanol

[X]aqueous

P is a measure of the relative affinity of a molecule for the lipid and aqueous phases in the absence of ionisation.

Partition coefficients

Page 25: Qsar and drug design ppt

LogP for a molecule can be calculated from a sum of fragmental or atom-based terms plus various corrections.

logP = fragments + corrections

C: 3.16 M: 3.16 PHENYLBUTAZONEClass | Type | Log(P) Contribution Description Value

FRAGMENT | # 1 | 3,5-pyrazolidinedione -3.240ISOLATING |CARBON| 5 Aliphatic isolating carbon(s) 0.975ISOLATING |CARBON| 12 Aromatic isolating carbon(s) 1.560EXFRAGMENT|BRANCH| 1 chain and 0 cluster branch(es) -0.130EXFRAGMENT|HYDROG| 20 H(s) on isolating carbons 4.540EXFRAGMENT|BONDS | 3 chain and 2 alicyclic (net) -0.540

RESULT | 2.11 |All fragments measured clogP 3.165

clogP for windows output

N

N

CC

CC

C

C

C

O

C

C

O

C

C

C

C

C

C

C

C

C

C

H

H

H

H

H H

H

HH

H

H

H

H

H

H

H

H

H

H

H

Phenylbutazone

Branch

Calculation of logP

Page 26: Qsar and drug design ppt

logPBinding to enzyme / receptor

Aqueous solubility

Binding to P450

metabolising enzymes

Absorption through membrane

Binding to blood / tissue proteins – less drug free to act

Binding to hERG heart ion channel -cardiotoxicity risk

So log P needs to be optimised

What else does logP affect?

Page 27: Qsar and drug design ppt

Admet Descriptors Admet Descriptors Calculation ToolsCalculation Tools PreADMET http://preadmet.bmdrc.org/ Molecular Descriptors Calculation - 1081 diverse molecular

descriptors Drug-Likeness Prediction - Lipinski rule, lead-like rule, Drug DB like

rule ADME Prediction  - caco-2, MDCK, BBB, HIA, plasima protein

binding and skin permeability data Toxicity Prediction - Ames test and rodent carcinogenicity assay SPARC Online Calculator

http://ibmlc2.chem.uga.edu/sparc/

SPARC on-line calculator for prediction of pK,, solubility, polarizability, and other properties; search in the database of experimental pKa values is also available

Daylight Chemical Information Systems

www.daylight .com/ daycgi/clogp

Calculation of log P by the CLOGP algorithm from BioByte; also access to the LOGPSTARdatabase of experimental log P data .

Page 28: Qsar and drug design ppt

Admet Tools Continued..Admet Tools Continued.. Molinspiration Cheminformatics

www.molinspiration.com/seruices/index.

Calculation of molecular properties relevant to drug design and QSAR, including log P, polar surface area, Rule of Five parameters, and drug-likeness index

Pirika - www.pirika.com

Calculation of various types of molecular properties, including boiling point, vapor pressure, and solubility; web demo restricted to only aliphatic molecules

Actelion -www.actelion.com/page/property_explorer

Calculation of molecular weight, logP, solubility, drug-score and toxlcity risk .

Virtual Computational Chemistry Laboratory www. vcclab. org

Prediction of log P and water solubility based on associative neural networks as well as other parameters; comparison of various prediction methods

Page 29: Qsar and drug design ppt

Virtual Screening Virtual Screening

Page 30: Qsar and drug design ppt

Ways to Assess Structures from Ways to Assess Structures from a Virtual Screening Experimenta Virtual Screening ExperimentUse a previously derived

mathematical model that predicts the biological activity of each structure

Run substructure queries to eliminate molecules with undesirable functionality

Use a docking program to ID structures predicted to bind strongly to the active site of a protein (if target structure is known)

Filters remove structures not wanted in a succession of screening methods

Page 31: Qsar and drug design ppt

Main Classes of Virtual Main Classes of Virtual Screening MethodsScreening MethodsDepend on the amount of structural and

bioactivity data available◦ One active molecule known: perform similarity

search (ligand-based virtual screening)◦ Several active molecules known: try to ID a

common 3D pharmacophore, then do a 3D database search

◦ Reasonable number of active and inactive structures known: train a machine learning technique

◦ 3D structure of the protein known: use protein-ligand docking

Page 32: Qsar and drug design ppt

STRUCTURE-BASEDSTRUCTURE-BASED VIRTUAL VIRTUAL SCREENINGSCREENINGProtein-Ligand Docking

◦ Aims to predict 3D structures when a molecule “docks” to a protein Need a way to explore the space of possible

protein-ligand geometries (poses) Scoring of the ligand poses uch that the score

reflects binding affinity of the ligand; Need to score or rank the poses to ID most likely

binding mode and assign a priority to the molecules

◦ Problem: involves many degrees of freedom (rotation, conformation) and solvent effects

Conformations of ligands in complexes often have very similar geometries to minimum-energy conformations of the isolated ligand

Page 33: Qsar and drug design ppt

Protein-Ligand Docking Protein-Ligand Docking MethodsMethodsModern methods explore orientational

and conformational degrees of freedom at the same time◦ Monte Carlo algorithms (change

conformation of the ligand or subject the molecule to a translation or rotation within the binding site

◦ Genetic algorithms◦ Incremental construction approaches

Page 34: Qsar and drug design ppt

Distinguish “Docking” and Distinguish “Docking” and “Scoring”“Scoring”

Docking involves the prediction of the binding mode of individual molecules◦ Goal: ID orientation closest in geometry to

the observed X-ray structureScoring ranks the ligands using some

function related to the free energy of association of the two units◦ DOCK function looks at atom pairs of

between 2.3-3.5 Angstroms◦ Pair-wise linear potential looks at attractive

and repulsive regions, taking into account steric and hydrogen bonding interactions(eg moldock)

Page 35: Qsar and drug design ppt

Structure-Based Virtual Structure-Based Virtual Screening: Other AspectsScreening: Other AspectsComputationally intensive and complexMultitude of possible parameters figure

into docking programsDocking programs require 3D

conformation as the starting point or require partial atomic charges for protein and ligand

X-Ray Crystallographic studies don’t include hydrogens, but most docking programs require them.

Page 36: Qsar and drug design ppt

Ligand Based Virtual ScreeningLigand Based Virtual Screening The Ligand based approach mainly uses pharmacophore maps and

(QSAR) to identify or modify a lead in the absence of a known three dimensional structure of the receptor. It is necessary to have experimental affinities and molecular properties of a set of active compounds, for which the chemical structures are known.

a)PHARMACOPHORE:A pharmacophore is an explicit geometric hypothesis of the critical features of a ligand.Standard features include H-bond donors and acceptors, charged groups,and Hydrophobic patterns.The hypothesis can be used to screen databases for compounds and to refine existing leads.

For a geometric alignment of the functional groups of the leads, it is necessary to specify the conformations that individual compounds adopt in their bound state.

Since the simple presence of a pharmacophoric fingerprint is not sufficient for predicting activity, inactive compounds possessing the required pharmacophoric features must also be considered.

By comparing the volume of the active and the inactive compounds, a common volume can be constructed in order to approximate the shape of the (unknown) receptor site to further refine the pharmacophore model and to screen out additional compounds.

Page 37: Qsar and drug design ppt

3D compound Structures

Feature Analysis

Set of Conformers

Align to template

compare

validation

Pharmacophore

Application

Pharmacophore Modelling Workflow

Page 38: Qsar and drug design ppt

Continued.......Continued.......

b)QSAR: The goal of QSAR studies is to predict the activity of new compounds based solely on their chemical structure. The underlying assumption is that the biological activity can be attributed to incremental contributions of the molecular fragments determining the biological activity. This assumption is called the linear free energy principle. Information about the strength of interactions is captured for each compound by,for example, steric,electronic,and hydrophobic descriptors.

Page 39: Qsar and drug design ppt

Molecular similarity and searching MoleculesMolecular similarity and searching Molecules

Chemical, pharmacological or biological properties of two compounds match.

The more the common features, the higher the similarity between two molecules.

Chemical

Pharmacophore

What is it?

The two structures on top are chemically similar to each other. This is reflected in their common sub-graph, or scaffold: they share 14 atoms

The two structures above are less similar chemically (topologically) yet have the same pharmacological activity, namely they both are Angiotensin-Converting Enzyme (ACE) inhibitors

Page 40: Qsar and drug design ppt

Molecular similarityMolecular similarity

How to calculate it?

)&()()(

)&(),(

yxByBxB

yxByxT

n

iii yxyxE

1

2),(

Sequences/vectors of bits, or numeric values that can be compared by distance functions, similarity metrics .

E= Euclidean distance T = Tanimoto index

Quantitative assessment of similarity/dissimilarity of structuresneed a numerically tractable formmolecular descriptors, fingerprints, structural keys

Page 41: Qsar and drug design ppt

hashed binary fingerprinto encodes topological properties of the chemical graph: connectivity,

edge label (bond type), node label (atom type)o allows the comparison of two molecules with respect to their

chemical structure

Molecular descriptorsMolecular descriptors

a) chemical fingerprint

Construction

1. find all 0, 1, …, n step walks in the chemical graph2. generate a bit array for each walks with given number of bits set3. merge the bit arrays with logical OR operation

Page 42: Qsar and drug design ppt

Molecular descriptorsMolecular descriptors

Example 1: chemical fingerprint

ExampleCH3 – CH2 – OH walks from the first carbon atom

length walk bit array

0 C 1010000000

1 C – H 0001010000

1 C – C 0001000100

2 C – C – H 0001000010

2 C – C – O 0100010000

3 C – C – O – H 0000011000

merge bit arrays for the first carbon atom: 1111011110 This example illustrates how a 10 bits long topological chemical fingerprint is

created for a simple chain structure. In this example all walks up to 3 steps are considered, and 2 bits are set for each pattern.

Page 43: Qsar and drug design ppt

Molecular SimilarityMolecular Similarity

Example 1: chemical fingerprint

0100010100010100010000000001101010011010100000010100000000100000

0100010100010100010000000001101010011010100000000100000000100000

Page 44: Qsar and drug design ppt

Molecular descriptorsMolecular descriptors

Example 2: pharmacophore fingerprint

encodes pharmacophore properties of molecules as frequency counts of pharmacophore point pairs at given topological distance

allows the comparison of two molecules with respect to their pharmacophore

Construction

1. map pharmacophore point type to atoms2. calculate length of shortest path between each pair of atoms3. assign a histogram to every pharmacophore point pairs and count

the frequency of the pair with respect to its distance

Page 45: Qsar and drug design ppt

Molecular descriptorsMolecular descriptors

Example 2: pharmacophore fingerprint

Pharmacophore point type based coloring of atoms: acceptor, donor, hydrophobic, none.

AA1

AA2

AA3

AA4

AA5

AA6

DA1

DA2

DA3

DA4

DA5

DA6

DD1

DD2

DD3

DD4

DD5

DD6

HA1

HA2

HA3

HA4

HA5

HA6

HD1

HD2

HD3

HD4

HD5

HD6

HH1

HH2

HH3

HH4

HH5

HH6

0

1

2

3

4

5

6

7

8

9

10

11

12

AA1

AA2

AA3

AA4

AA5

AA6

DA1

DA2

DA3

DA4

DA5

DA6

DD1

DD2

DD3

DD4

DD5

DD6

HA1

HA2

HA3

HA4

HA5

HA6

HD1

HD2

HD3

HD4

HD5

HD6

HH1

HH2

HH3

HH4

HH5

HH6

0

1

2

3

4

5

6

7

8

9

10

11

12

Page 46: Qsar and drug design ppt

000000010000110100000010101000000000011000001000010000100000100001000101100100100101100110100111001111010000001100000001100010000100010100011101010000110000101000010011000010100000000100100000000110111001110111111010000010001000011011011000000010011010000001000101001101000100000000100000000100100000001001000010001010000100011100011101000100001011101100110110010010001101001100001000010111010011010101011111100001000001111110001000010000100010100001000101001111010100001000100000000100100000101001000010001010000001000100010100010100100000000000001010000010000100000100000000010001010001001100000000000000000001010000001000000000000000000001000101000101000000000000001010000100100000000001000000000000000101010101111100111110100000000000011010100011100100001100101000010001010001100001000001100000000001000100000011000000000110000000000001000000000100001000000000000010101000000001000001001000000100010100010100000000100000000000010000000000000100001000011000000100010000110001001010000001010010101110001000010000100010100001000111000101000100001000010011100100100000100011000000001010000101010100010100010100100000000000010010000010010100100100010000

query

targets

query fingerprint

proximity

target fingerprints

hits

0101010100010100010100100000000000010010000010010100100100010000

Virtual screening using fingerprintsVirtual screening using fingerprints

Individual query structure

Page 47: Qsar and drug design ppt

Hypothesis FingerprintsHypothesis FingerprintsAdvantages Disadvantages

•strict conditions for hits if actives are fairly similar

• false results with asymmetric metrics

•misses common features of highly diverse sets

•very sensitive to one missing feature

•captures common features of more diverse active sets

• less selective if actives are very similar

•captures common features of more diverse active sets

•specific treatment of the absence of a feature

• less sensitive to outliers

• less selective if actives are very similar

Page 48: Qsar and drug design ppt

SUMMARYSUMMARYVirtual screening methods are central

to many cheminformatics problems in:◦ Design◦ Selection◦ Analysis

Increasing numbers of molecules can be evaluated using these techniques

Reliability and accuracy remain as problems in docking and predicting ADMET properties

Need much more reliable and consistent experimental data

Page 49: Qsar and drug design ppt

Datamining and Machine Datamining and Machine Learning Approaches to Learning Approaches to Virtual ScreeningVirtual Screening

Page 50: Qsar and drug design ppt

Idea of Datamining Idea of Datamining Is discovering for patterns in the

data i.e for example a)an hunter looks pattern in animal migration

behavior. b)farmers seek patterns in crop growth. c) politcians seek patterns in voters opinion d) Pattern in the compound structures .The Patterns which are discovered must

be meaningful and lead to some advantage.

The process must be automatic or semiautomatic.

Page 51: Qsar and drug design ppt

Canonical learning Canonical learning ProblemsProblems

Supervised Learning: given examples of inputs and corresponding desired outputs, predict outputs on future inputs.

a) Classification b) Regression c) Time series predictionUnsupervised Learning: given only inputs,

automatically discover representations, features, structure, etc.

a) Clustering b) Outlier detection c) Compression

Page 52: Qsar and drug design ppt

Datamining MethodsDatamining MethodsSubstructural Analysis The Substrcutural fragments makes a contribution to

activity irrespective of the other fragments of the molecule. The idea is to derive a weight for each fragment which reflects to be active or inactive. The sum of weight gives the score of molecule which enables a new set of structures to be ranked in Decreasing probability of activity.

The weight is calculated using the eq :

Where act(i) is the number of active molecules that contain the i th fragment and inact(i) is the number of inactive molecules that contain the i th fragment

Page 53: Qsar and drug design ppt

Discriminant algorithmsDiscriminant algorithms The aim of discriminant analysis is try to

separate the molecules into constituent classes. The simplest Linear discriminant which in case

of two activity class and two descriptors which aim to find a st. line that separates data such that maximum number of compounds are classified.

If more than variable uses the line become hyperplane.

The idea is to express a class as a linear combination of attributes.

X= w0+w1a1+w2a2+w3a3+.........

X =class a1 a2 = attributes w1 w2 = weights

Page 54: Qsar and drug design ppt

Neural Networks(NN)Neural Networks(NN) The two most commonly used neural network

architectures used in chemistry are the feed forward networks and the Kohonen networks.

The feed forward NN is a supervised learning method as it uses the values of dependent variables to derive the model. The Kohonen or Self Organizing map (SOM) is an unsupervised method.

The Feed forward NN contains layers of nodes with connection between all pairs of nodes in the adjacent layers. A key feature is presence of hidden nodes along with back propagation algorithm makes the network applicable to many fields.

The neural network must first be trained with set of inputs. Once it has been trained it can then be used to predict values for new and unseen molecules.

Page 55: Qsar and drug design ppt

Neural Networks Neural Networks Continued...Continued...

The Figure Below shows a Feed forward network with 3Hidden nodes and one output.

A Kohonen NN consist of rectangular array of nodes and each nodes associates a vector that corresponds to input data (Descriptors values)

The data is presented to the network one molecule at a time and the distance between each of node vectors and molecule vectors are determined with distance metric. The node with minimum distance becomes the wining node.

Page 56: Qsar and drug design ppt

Disadvantage of Neural Disadvantage of Neural NetworksNetworks Its is difficult to design a perfect model for neural

networks with number of hidden layers and nodes which will best fit the data.

Another practical issue is Overtraining .An overtrained NN will give excellent results train data but will perform poorly on an unseen data(test data).This is because the network memorizes the data.

The way solve this problem is to divide the sets in train and test and then watch performance of the set . If the performance of the test set increase such that till it reaches a plateau and start to decline ,at this point network has maximum predictive ability.

Page 57: Qsar and drug design ppt

DECISION TREES(DT)DECISION TREES(DT) In Feed forward NN it is not possible to determine the

result for a given input due to complex nature of interconnection between nodes one cannot determine which properties are important.

Decision trees consist of set of rules that associate molecular descriptor values with property of interest.

A DT is a tree with nodes containing specific rules .Each Rule may correspond to the presence or absence of a particular feature .

In a DT one start at the root node and follows the edge with appropriate first rule. This continues until a terminal node is reached at which point one can assign the molecule into active and inactive class.

DTs like ID3 ,C4.5,C 5.0 uses information theory to choose which criteria to choose at each step.

Random forests a small subset of the descriptors is randomly selected at each node rather than using the full set.

Page 58: Qsar and drug design ppt

Support Vector Support Vector Machines(SVM)Machines(SVM)

Support vector machines select a small number of critical boundary instances called support vectors from each class and build a linear discriminant function that separates them as widely as possible.

Molecules in the test set are mapped to the same feature space and

their activity is predicted according to which side of the hyper plane they fall.

The distance to the boundary can be used to assign confidence level to the prediction such that higher the distance the higher the confidence.

The output of SVM is given by f(x)=sign(g(x)) where g(x)=w(t)x+b, w is a vector and b is a scalar.

linear SVM can be applied only when the active and inactive compounds can be divided by a straight line (hyperplane) in the feature space.

Page 59: Qsar and drug design ppt

SVM continued....SVM continued.... When the data cannot be separated linearly, kernel

functions are used to transform to the Higher dimensions.

The output of SVM is given by f(x)=sign(g(x)) and g(x) is given by

  where K is the so-called kernel function, the suffix k

represents the support vector, and m stands for the number of support vectors.

The Gaussian and the Polynomial kernel function are used

Page 60: Qsar and drug design ppt

Strengths and Weaknesses Strengths and Weaknesses of SVMof SVM

Strengths Training is relatively easy No local optima It scales relatively well to high dimensional data Tradeoff between classifier complexity and error can

be controlled explicitly Non-traditional data like strings and trees can be used

as input to SVM, instead of feature vectors

WeaknessesNeed to choose a “good”kernel function.

Page 61: Qsar and drug design ppt

Measuring Classifier Measuring Classifier PerformancePerformance

N= total number of instances in the dataset

TPj= Number of True Positives for class j

FPj = Number of False positives for class j

TNj= Number of True Negatives for class j

FNj= Number of False Negatives for class j

Accuracy =

Sensitivity/recall =

Specificity/precision =

Page 62: Qsar and drug design ppt

Types of Datamining Types of Datamining learning learning Process in Weka Process in WekaClassification- learning-the learning scheme

is presented with a set of classified examples from which it is expected to learn a way of classifying unseen examples.

Association Learning-any association among features is sought, not just ones that predict a particular class value

Clustering-groups of examples that belong together are sought

Numeric prediction-the outcome to be predicted

is not a discrete class but a numeric quantity.

Page 63: Qsar and drug design ppt

Classifier Algorithms in Classifier Algorithms in WEKAWEKAa)Bayes Classifier c) Functions AODE LINEAR REGRESSION BAYES NET LOGISTIC NAÏVE BAYES MULTILAYERD PERCEPTRON NAÏVE BAYES MULTINOMIAL RBF NETWORK NAÏVE BAYES UPDATABLE SIMPLE LINEAR REGRESSION SIMPLE LOGISTIC

SMO,SMO REG. b)Trees d)Rules ADTREE CONJUCTIVE RULEID3 DECISION TABLE J48 JRIPLMT M 5RULES

NB5TREE NNGERANDOM FOREST ONE R RANDOM TREE PRISMREP TREE ZERO R

Page 64: Qsar and drug design ppt

SummarySummary Machine learning is mainly applied to ligand-based

drug screening and it is applied to the calculation of the optimal distance between the feature vectors of active and inactive compounds.

A kernel is essentially a similarity function with certain mathematical properties, and it is possible to define kernel functions over all sorts of structures for example, sets, strings, trees, and probability distributions .

Interest in neural networks appears to have declined since the arrival of support vector machines, perhaps because the latter generally require fewer parameters to be tuned to achieve the same (or greater) accuracy.

Page 65: Qsar and drug design ppt

THANK YOUTHANK YOU